Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Hexima Limited
  6. News
  7. Summary
    HXL   AU0000111932

HEXIMA LIMITED

(HXL)
SummaryChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Hexima Limited Announces Completion of Enrolment in Phase IIb Clinical Trial

07/25/2021 | 08:59pm EDT

Hexima Limited announced that it has completed enrolment of patients into its phase IIb clinical trial evaluating pezadeftide (HXP124) as a potential new topical treatment for onychomycosis. The study is on schedule and Hexima expects to announce results from the trial in second quarter of 2022. This is an important achievement in pezadeftide's advanced clinical development program. Fifteen clinical sites across Australia and New Zealand enrolled a total of 117 patients into the study. Patients were randomly assigned to three different treatment arms. In each treatment arm patients receive either pezadeftide or the vehicle (without pezadeftide) control. The assignment of vehicle versus active is blinded to both the patient and the investigator. Patients will be monitored at follow-up visits for the safety and efficacy of pezadeftide through to the end of the study. The study also collects patient satisfaction measures. Hexima expects this phase IIb clinical trial to represent its last large multi-centre clinical trial ahead of initiating a phase III program in third quarter of 2022. In preparation, Hexima expects to file an IND with FDA in fourth quarter of 2021 and then conduct an FDA-required small single-centre, maximal use, safety study in the US in first half of 2022.


© S&P Capital IQ 2021
All news about HEXIMA LIMITED
08/31Jake Nunn Joins Board of Hexima Limited as Non-Executive Director, effective ..
CI
08/27HEXIMA : 2021 Annual Financial Report
PU
08/27Hexima Limited Reports Earnings Results for the Full Year Ended June 30, 2021
CI
08/27Hexima Limited Auditor Raises 'Going Concern' Doubt
CI
08/24HEXIMA : Secures Chinese Patent for Fungal Nail Infection Treatment; Shares Surg..
MT
08/18Hexima Limited Announces Design Patent for Pezadeftide Commercial Packaging
CI
07/25Hexima Limited Announces Completion of Enrolment in Phase IIb Clinical Trial
CI
07/13HEXIMA : Expects to Secure European Patent for Nail Fungal Infection Treatment
MT
07/13Hexima Limited Extends Its Patent Protection for Pezadeftide
CI
05/21HEXIMA : Fungal Nail Infection Treatment Receives INN Designation
MT
More news
Financials
Sales 2021 4,08 M 2,98 M 2,98 M
Net income 2021 -6,87 M -5,02 M -5,02 M
Net cash 2021 3,39 M 2,48 M 2,48 M
P/E ratio 2021 -2,77x
Yield 2021 -
Capitalization 58,2 M 42,4 M 42,6 M
EV / Sales 2020 -
EV / Sales 2021 4,62x
Nbr of Employees -
Free-Float 42,3%
Chart HEXIMA LIMITED
Duration : Period :
Hexima Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Michael Douglas Arthur Aldridge CEO, Non-Independent Non-Executive Director & MD
Jonathan West Non-Executive Chairman
Marilyn Ann Anderson Executive Director & Chief Scientific Officer
Yolanda Gaspar Head-Clinical Operations
Nicole Louise van der Weerden Chief Operating Officer & Executive Director
Sector and Competitors
1st jan.Capi. (M$)
HEXIMA LIMITED140.54%42
MODERNA, INC.321.80%177 867
LONZA GROUP AG36.36%62 278
IQVIA HOLDINGS INC.43.91%49 407
CELLTRION, INC.-25.63%31 021
SEAGEN INC.-12.32%27 940